On December 4th, 2024, National Geographic published an article featuring insights from AFAR Grantees Matt Kaeberlein, PhD, and Dudley Lamming, PhD, on Rapamycin and the future of therapeutics to extend healthspan and treat or delay age-related disease.
Dr. Kaeberlein shared insights from the Dog Aging Project, which he co-founded with fellow AFAR grantee Daniel Promislow, DPhil. The project is exploring the effects of different therapeutics, soon to include Rapamycin, on canine longevity and healthspan, helping to advance our understanding of aging and its potential implications on human healthspan.
Dr. Lamming emphasized the importance of clinical trials focused on targeting the biology of aging to extend healthspan for validating a drug’s potential effectiveness as a gerotherapeutics.
Dr. Kaeberlein is a 2006 Glenn Foundation for Medical Research and AFAR Grants for Junior Faculty recipient, and a 2007 Glenn Foundation for Medical Research Breakthroughs in Gerontology (BIG) Award recipient. He is also the 2011 recipient of AFAR’s Vincent Cristofalo Rising Star Award in Aging Research.
Dr. Dudley Lamming is a 2015 Glenn Foundation for Medical Research and AFAR Research Grant for Junior Faculty recipient.
Read the article, “Can this ‘anti-aging’ drug live up to the hype? Here’s what we know,” here.
